News

MAVYRET is an 8-week, pan-genotypic treatment for patients without cirrhosis and who are new to treatment. Up to 95 percent of HCV patients in the U.S. may be

According to the agreement, HitGen will use its advanced technology platform, based on DNA-encoded library design, synthesis and screening to discover novel leads which will be licensed exclusively

According to Lilly, the primary endpoint of the phase 3 SPARTAN trial was comparison of the percentage of patients in the lasmiditan 200mg and placebo groups who were

Cardurion, a recently launched Boston-area based biotechnology company, is focused on the development of novel, next-generation therapeutics for the treatment of heart failure and other cardiovascular diseases. Cardurion

Although, the FDA is not obliged to go by the recommendation of the committee, more often or not it takes its advice into consideration. The drug, which is

A venture-backed biotech company, IFM Therapeutics is into developing therapies that regulate novel targets in the innate immune system for the treatment of cancer, autoimmunity and inflammatory disorders.

CEO of Orbsen Therapeutics, Dr Larry Couture, commented: “This approval is an important step toward the clinical demonstration of the tremendous potential of Orbsen’s ‘off-the-shelf’ allogeneic ORBCEL-M second

The NDA is based on results from the Phase II ACE-LY-004 clinical trial, which evaluated the safety and efficacy of acalabrutinib in patients with relapsed/refractory mantle cell lymphoma

Marketed as Tecentriq, atezolizumab was assessed by NICE as a treatment option for patients with advanced urothelial cancer. The UK drug watchdog has suggested Roche to file a